By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Media HydeMedia Hyde
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Font ResizerAa
Media HydeMedia Hyde
Font ResizerAa
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Follow US
© 2026 Media Hyde Network. All Rights Reserved.
HeadlineHealth

AstraZeneca Halts Lung Cancer Trial After Drug Fails Efficacy Test

Last updated: August 18, 2026 12:56 am
Haris Ali
Share
AstraZeneca Halts Lung Cancer Trial After Drug Fails Efficacy Test
AstraZeneca Halts Lung Cancer Trial After Drug Fails Efficacy Test
SHARE

AstraZeneca has pulled the plug on a late-stage trial for volrustomig, a drug intended to treat non-small cell lung cancer. The company confirmed on Wednesday that an independent data monitoring committee found the treatment unlikely to meet its primary goal of improving patient outcomes compared to current standards.

This marks a significant blow to the pharmaceutical giant’s oncology pipeline. Volrustomig, a bispecific antibody, was designed to hit two targets simultaneously—PD-1 and CTLA-4—aiming to supercharge the immune system’s ability to hunt down cancer cells.

The study, dubbed eVOLVE-Lung02, was testing the drug in patients who had already seen their cancer progress after initial chemotherapy and immunotherapy. AstraZeneca had hoped for a breakthrough in a crowded market, but the interim analysis showed the drug simply didn’t clear the bar.

“While we are disappointed that this trial did not reach its primary endpoint, the data provides essential insights into the complexity of treating advanced lung cancer,” a company spokesperson said in a statement. They added that the focus now shifts to winding down the study and analyzing the data to inform future research.

The failure hits at a sensitive time for AstraZeneca. Investors have been closely watching the company’s push to diversify its cancer portfolio beyond its blockbuster drug, Tagrisso. Volrustomig was intended to be a cornerstone of that expansion, positioning the company to compete with other major players fighting for dominance in the immuno-oncology space.

For patients, the news is a setback. Many in the trial had few remaining treatment options, and the failure leaves a void in the development of dual-target therapies.

AstraZeneca’s stock saw a marginal dip following the announcement, reflecting broader market anxiety over the success rate of complex, high-stakes clinical trials. The company now faces the task of recalibrating its lung cancer strategy, with analysts waiting to see if other ongoing trials in their pipeline can recover the lost momentum.

The company will present the full findings at an upcoming medical conference, but for now, the development of volrustomig in this specific setting is over.

Share This Article
Email Copy Link Print
Previous Article NICVD greenlights advanced heart failure program to tackle rising cardiac cases NICVD greenlights advanced heart failure program to tackle rising cardiac cases
Next Article Saudi Arabia Imposes SR200,000 Fines for Water Waste Saudi Arabia Imposes SR200,000 Fines for Water Waste
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sponsored Ads

Stay Connected

FacebookLike
XFollow
InstagramFollow
YoutubeSubscribe
WhatsAppFollow
ThreadsFollow
Panchayat Season 5 Release Date Announced Jitendra Kumar and Neena Gupta Return to Phulera
Panchayat Season 5 Release Date Announced Jitendra Kumar and Neena Gupta Return to Phulera
Entertainment
November 18, 2026
Nameer Khan Reveals His Journey from Software Engineer to Actor
Nameer Khan Reveals His Journey from Software Engineer to Actor
Entertainment
November 18, 2026
Aiman Khan and Muneeb Butt Honoured at British Parliament
Aiman Khan and Muneeb Butt Honoured at British Parliament
Entertainment
November 18, 2026
PTI Questions Bilawal Bhutto-Zardari Over Late Realisation of Public Hardships
PTI Questions Bilawal Bhutto-Zardari Over Late Realisation of Public Hardships
Politics
November 18, 2026
Nawaz Sharif Vows to Accelerate Development in Azad Kashmir Under 100-Day Plan
Nawaz Sharif Vows to Accelerate Development in Azad Kashmir Under 100-Day Plan
Politics
November 18, 2026
Pakistan faces internet slowdown after submarine cable develops fault
Pakistan faces internet slowdown after submarine cable develops fault
Headline Technology
November 18, 2026

You Might Also Like

Health

Why Does Cholesterol Increase in the Body?

By
Neha Ashraf
Salmonella Outbreak Strikes Belgium: Over 300 Infected
HeadlineHealth

Salmonella Outbreak Strikes Belgium: Over 300 Infected

By
Haris Ali
Total Lunar Eclipse Drapes Night Sky in Crimson Hue
Climate and WeatherHeadline

Total Lunar Eclipse Drapes Night Sky in Crimson Hue

By
Ayesha Masood
Tehran Rips US-GCC Statement on 'Iran Threats' as Provocative
HeadlinePolitics

Tehran Rips US-GCC Statement on ‘Iran Threats’ as Provocative

By
Ayesha Masood
Media Hyde Media Hyde Dark
Facebook Twitter Youtube Rss Medium

About US

Media Hyde Network: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 News.

Top Categories
  • Headline
  • Politics
  • Entertainment
  • Education
  • Sports
  • Religious
  • Metropolitan
  • Climate and Weather
Usefull Links
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Cookies Policy
  • Advertising Policy
  • Terms & Conditions

© 2025 Media Hyde Network. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?